A Live Attenuated Equine Infectious Anemia Virus Proviral Vaccine with a Modified S2 Gene Provides Protection from Detectable Infection by Intravenous Virulent Virus Challenge of Experimentally Inoculated Horses
Open Access
- 1 July 2003
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 77 (13) , 7689-7695
- https://doi.org/10.1128/jvi.77.13.7244-7253.2003
Abstract
Previously we showed that recombinant adenoviral helper-dependent (HD) vectors result in long-term transgene expression levels in vivo which slowly declined by 95% over a period of 1 year. In this study, we further establish that this was not predominantly immune mediated. To determine if cell turnover was responsible for the loss of transgene expression, we induced rapid hepatocyte cell cycling in mouse liver, by performing a surgical two-thirds partial hepatectomy. We observed a 55 and 65% reduction in transgene expression levels and a 50 and 71% loss of vector genomes for the HD vector and the first-generation adenoviral vector. In sharp contrast, in nonviral, episomal plasmid DNA-injected mice, transgene expression levels and DNA copy numbers decreased by 95 and 99%, respectively. These findings suggest that cell division alone was not the primary reason for the slow decrease in transgene expression levels and that recombinant adenoviral vectors have a more robust mechanism for maintaining persistence during cell cycling. Several potential mechanisms are proposed.Keywords
This publication has 50 references indexed in Scilit:
- Equine Infectious Anemia Virus Genomic Evolution in Progressor and Nonprogressor PoniesJournal of Virology, 2001
- Protection of Macaques against a SHIV with a Homologous HIV-1 Env and a Pathogenic SHIV-89.6P with a Heterologous Env by Vaccination with Multiple Gene-Deleted SHIVsVirology, 1999
- Evaluation of Antibody Parameters as Potential Correlates of Protection or Enhancement by Experimental Vaccines to Equine Infectious Anemia VirusVirology, 1999
- A Particulate Viral Protein Vaccine Reduces Viral Load and Delays Progression to Disease in Immunized Ponies Challenged with Equine Infectious Anemia VirusVirology, 1999
- Immunization with a Recombinant Envelope Protein (rgp90) of EIAV Produces a Spectrum of Vaccine Efficacy Ranging from Lack of Clinical Disease to Severe EnhancementVirology, 1998
- Short Communication: A Novel Mutation (F227L) Arises in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 on Dose-Escalating Treatment of HIV Type 1-Infected Cell Cultures with the Nonnucleoside Reverse Transcriptase Inhibitor Thiocarboxanilide UC-781AIDS Research and Human Retroviruses, 1998
- A model for the maturation of protective antibody responses to SIV envelope proteins in experimentally immunized monkeysJournal of Medical Primatology, 1997
- Characterization of Protective and Enhancing Immune Responses to Equine Infectious Anemia Virus Resulting from Experimental VaccinesAIDS Research and Human Retroviruses, 1996
- Equine RetrovirusesPublished by Springer Nature ,1993
- Equine infectious anemia virus (EIAV) Humoral responses of recipient ponies and antigenic variation during persistent infectionArchiv für die gesamte Virusforschung, 1990